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Medical devices are being used in healthcare facilities for diagnosis,  
monitoring, prevention and treatment of an array of diseases. To ensure user/
patient safety associated with the medical devices being used in healthcare indus-
try, it is of utmost importance to closely monitor the adverse events associated 
with the medical devices through a robust, sustainable and scaled surveillance. 
Materiovigilance Programme of India (MvPI) provides a reliable system to report 
adverse events associated with medical devices. Under MvPI, various modalities 
to report adverse events associated with medical devices have been developed. 
These modalities include an editable medical device adverse event reporting form, 
a toll-free helpline number and a field safety corrective action form (FSCA). 
FSCA form is used to notify the regulatory authority and healthcare professionals 
on corrective actions or recall by the manufacturer. Due to the emergence of the 
Coronavirus disease 2019 (COVID-19) pandemic, one-page editable form has been 
developed to boost the adverse event reporting of Personal Protective Equipments 
(PPEs). MvPI also coordinates with healthcare facilities and medical device indus-
tries across the country for reporting the medical device-related adverse events. 
The collected scientific data is utilized to develop regulatory policies and enhance 
measures to ensure the quality of medical devices. All the healthcare workers 
are, therefore, encouraged to report adverse events to MvPI. This chapter aims 
to describe the systems, procedures and modalities available for the reporting of 
Medical Device Adverse Events (MDAEs) in India, in order to intensify the nature 
of reporting and creating an environment that encourages the public to perform 
MDAE reporting.
Keywords: Adverse event, COVID-19, Materiovigilance Programme of India, 
Personal Protective Equipments, Causality assessment, Medical device
1. Introduction
Over the last years, medical devices have been playing a pivotal role in the 
diagnosis and management of a variety of diseases [1]. With the advancement in the 
technology and increased public demand for high quality medical care, the global 
medical device industry has surpassed USD 350 billion in annual revenue, and in 
India a growth rate of 20% has been seen in healthcare industry. These devices have 
also created substantial risks to the patients with high profile recalls [2]. Nearly 
5,000 individual classes of medical devices, tens of thousands of medical device 
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suppliers, and millions of healthcare providers exist worldwide, which clearly 
depicts that device-related issues are likely to occur. The outcome of an adverse 
event related to medical devices can be serious and result in illness, injury or even 
death, which have led experts to call for the monitoring of the safe and effective use 
of medical devices after its regulatory approval [3].
Materiovigilance Programme of India (MvPI) was launched in 2015 and has 
implemented a robust system to ensure the safety of medical devices. The aim of 
this programme is to identify the adverse events associated with the use of medical 
devices and to eliminate the device-related risks through a systematic reporting 
system [4]. In India, the Medical Devices Rules (MDR) were notified on January 
31st, 2017 and became effective from January 1st, 2018. As per the MDR, G.S.R. 78 
(E), Chapter 4, Section 26 (ii) “the License Holder shall inform the State Licensing 
Authority (SLA) or Central Licensing Authority (CLA), as the case may be of the 
occurrence of any suspected unexpected serious adverse events and take necessary 
action thereon, including any recall within 15 days of such event coming to the 
notice of License Holder” [5] (Table 1). The MDR, in concurrence with MvPI, has 
significantly influenced the post marketing surveillance of medical devices among 
the healthcare professionals, by ensuring their quality and patient/user safety [5]. 
This chapter aims to describe the systems, procedures and modalities available 
for the reporting of Medical Device Adverse Events (MDAEs) in India, in order to 
intensify the nature of reporting and creating an environment that encourages the 
public to perform MDAE reporting.
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2. MvPI Focus Groups for MDAE reporting
The following groups play a significant role in the smooth functioning 
of MvPI:
2.1  Medical Device Adverse Event Monitoring Centres (MDMCs) and Adverse 
Drug Reactions Monitoring Centres (AMCs)
Healthcare facilities, including district/government/private hospitals, and 
autonomous bodies are recognized as MDMCs and AMCs by the NCC-MvPI, IPC 
and NCC-PvPI, IPC respectively. The function of the MDMC is to raise awareness 
about the programme and reporting of MDAEs. The MvPI collects reports from the 
MDMCs, AMCs. Under the MvPI, 50 MDMCs have been identified so far in India 
to collect the report of the events associated with the use of medical devices [6]. 
The AMCs established under the Pharmacovigilance Programme of India (PvPI) 
are also participating in MDAE reporting. Around 311 centres have been identified 
in the country to report the adverse events resulting from the use of drugs/medical 
products [7].
2.2 Medical device industries
Medical device industries, including manufacturers, importers, distributors, 
etc., are approached and encouraged to report the MDAE, particularly with their 
own medical devices. As there may be chances of re-occurrences of the adverse 
events, medical device industries play a key role in medical device safety  
surveillance [8].
2.3 Healthcare professionals
Healthcare facilities include healthcare professionals, such as clinical specialists, 
biomedical engineers, nurses, pharmacists, hospital technology managers, and 
technicians, as well as patients. Healthcare professionals are in direct contact both 
with the patients and the medical devices used in the healthcare facilities, and are 
hence the key personnel in MDAE reporting [9].
2.4 Accreditation bodies
Accreditation bodies essentially identify the capability of the hospitals to 
deliver quality care. Indian healthcare institutions get accreditation from bodies 
such as the National Accreditation Board for Hospitals and Healthcare providers 
(NABH). The IPC has signed a Memorandum of Understanding (MoU) with the 
NABH, under the Quality Council of India (QCI), to ensure for total cooperation of 
the hospitals on the reporting of adverse events associated with medical devices in 
the hospital [10].
3. Modalities for MDAE reporting
The NCC for MvPI, IPC has developed the below-mentioned reporting tools to 
collect MDAEs. All the reporting tools are available on the IPC website. The health-
care professionals, MAHs and all the Personal Protective Equipments (PPEs) users 
are encouraged to report adverse events associated with medical devices [11].
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3.1 MDAE reporting form
The MDAE reporting form primarily aims to collect the adverse events associated 
with the use of medical devices, In-Vitro Diagnostics (IVDs), and medical equip-
ments. The healthcare professionals and others including, but not limited to, manu-
facturers, importers, distributors, and hospital managers are solicited to report the 
adverse events for known, unknown, serious, non-serious, frequent or rare adverse 
events. The MDAE reporting form assembles adverse event information associated 
with medical devices and consists of the following nine sections (Figure 1) [11].
3.1.1 General information
This section includes the date of report, i.e. the date in which the report was filled, 
and the type of report that specifies whether the event is Initial/Follow-up/Final/Trend. 
The initial report is the first event notification report which may include the minimal 
required information, for instance, device information, details of adverse event 
and reporter details. A report may be marked as a follow-up report when additional 
information is available from the previously reported event. The report may be submit-
ted as a final report when all the information associated with the event is available and 
collected. If the reporter is observing a significant number of similar adverse events, 
the reporter may tick the trend option [12].
3.1.2 Reporter details
This section comprises the type of reporter, along with the details of the 
reporter, including name, address, contact number and e-mail address. A reporter 
may be a manufacturer, importer, distributor, healthcare professional, patient, or 
other. The information provided in this section is kept confidential and only utilised 
for further follow-up.
3.1.3 Device category
This section refers to the general information about the medical device used. The 
device category section in the MDAE reporting form consists of three subsections, 
namely medical device, medical equipment and IVDs. The medical equipment and 
IVDs subsections refer to specific categories of medical devices. Medical devices 
requiring calibration, maintenance, repair, user training and decommissioning – are 
usually managed by clinical engineers. Medical equipment is used for the specific 
purposes of diagnosis and treatment of disease or rehabilitation following disease or 
injury. It can be used either alone or in combination with any accessory, consumable 
or other piece of medical equipment. Medical equipment excludes implantable, dis-
posable or single-use medical devices. The IVD medical devices includes a medical 
device, used either alone or in combination, intended by the manufacturer for the 
in-vitro examination of specimens derived from the human body solely or princi-
pally to provide information for diagnostic, monitoring or compatibility purposes. 
All the other devices not covered under the definitions of medical equipments and 
IVDs should be included into the medical device subsection.
3.1.4 Device description
This section describes the specific details of the suspected medical device: device 
name or the brand name used for marketing of the device, manufacturing or import 
firm name and address, the information of local distributer, the lot/batch number, 
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serial number, year of manufacturing. Furthermore, in case of medical equipment, 
the additional information also includes installation date, last calibration date and 
preventive maintenance date, and software version is also asked. Many countries use 
different nomenclature systems for naming the medical device. The most prominent 
codes known are the Global Medical Device Nomenclature (GMDN) and Universal 
Medical Device Nomenclature System (UMDNS). In the reporting form, the reporter 
has an option to add the nomenclature code of the device while reporting the event.
Figure 1. 
Pictorial representation of medical device adverse event (MDAE) reporting form.
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3.1.5 Event description
This section includes the most important dates associated with the adverse 
event, such as the date in which the event or any near miss incident occurred, etc. 
Furthermore, this section also comprises the information about device operator, 
device location and the detailed description of the event. The reporter may mark an 
event as serious in case it fulfils the seriousness criteria described in MDR 2017 [5]. 
Otherwise, the event may be marked as non-serious.
3.1.6 Patient information
This section contains the patient information, including its medical history and 
final patient outcome after the adverse event has occurred. Additionally, the patient 
hospital ID, age, gender is also comprised in this section.
3.1.7 Healthcare facility information
This section includes the details of the hospital in which the event took place, 
as well as the details of a contact person at the hospital, for the further follow-up 
communication related to the adverse event.
3.1.8 Causality assessment
This section aims to collect the information regarding the investigation process 
carried out by the clinical specialists from the healthcare facility, or by the con-
cerned personnel from the manufacturing organization, to further drawing out the 
root cause of the problem and the immediate action taken to reverse the adverse 
effect, if possible. The root cause will ascertain the most likely reason for the 
occurrence of the adverse event.
3.1.9 Manufacturer/Authorized representative investigation & action taken
This section provides the information related to the investigation methods 
performed by the manufacturer/authorized representative and device history, 
which includes a review of similar events occurred from the same batch/lot, the 
analysis report of the event related to the medical device, and the corrective/
preventive action/recall taken to prevent the patient from being affected by 
the device, if any. The MDAE form is designed in such a manner that it collects 
the maximum information required, which may be helpful for the identifica-
tion of the MDAE and for creating the database of the medical device-related 
errors, thus enabling to trace the trend of adverse events associated with medi-
cal devices. The MDAE form may also help the medical device stakeholders to 
provide appropriate information and enhance the quality of the information 
collected.
3.2 PPE Reporting Form
During the prevailing situation regarding the COVID-19 pandemic, the 
NCC-MvPI specially designed a one-page editable MDAE reporting form, which 
primarily aims to collect the adverse events associated with the use of PPEs used 
for medical purposes (Figure 2) [11]. The information required to be filled in the 
reporting form under the different categories is as follows [11]:
7
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3.2.1 General information
This section includes the exact date in which the event was reported to the 
NCC-MvPI, IPC, and the type of report that specifies whether the event is 
Initial/Follow-up. The initial report is the first notification about an adverse 
Figure 2. 
Pictorial representation of personal protective equipment (PPE) reporting form.
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event submitted to the NCC-MvPI, IPC, once the reporter became aware of it. 
The follow-up report comprises the additional information about the  
previous report.
3.2.2 Reporter details
This section comprises the details of the reporter, including name, address, 
contact number and e-mail address. The information provided in this section is kept 
confidential and only utilized for the follow-up.
3.2.3 PPE type
This section encompasses the type of PPE involved in the adverse event/reaction- 
gloves, coverall, goggles, N-95 masks, shoe covers, face shields, body bags, triple 
layer medical mask, among others.
3.2.4 PPE details
This section describes the specific details of the PPE involved in the adverse 
event. These details include the brand name, manufacturer/importer/distributer 
name, batch number, model number, license number, unique certification code, test 
standard followed, manufacturing date and expiry date.
3.2.5 Location of event
This section refers to the location where the adverse event has occurred, and 
includes inpatient department, quarantine facilities, emergency department, etc.
3.2.6 Type of event
This section comprises the seriousness of the event. If the event involves 
the following outcomes: death/life threatening/disability or permanent dam-
age/hospitalization/congenital anomaly, then it should be marked as serious. 
Otherwise, the event may be marked as non-serious.
3.2.7 User details
This section covers the details of the PPE user, including user initials, age, 
gender, etc.
3.2.8 Event description
This section includes the detailed description of an adverse event associated 
with PPEs.
3.2.9 Hospital/quarantine facility details
This section provides the details related to the hospital/quarantine facilities, 
including name, address and contact person. The PPE form is designed in such 
a manner that it collects all the required information, which may be used for the 
identification of PPE-related adverse events and for creating the database of such 
adverse events.
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3.3 Field safety corrective action (FSCA) notification form
The FSCA [11] refers to any action taken to reduce a risk of death or serious 
deterioration in the state of health associated with the use of a medical device, 
including the: (i) device returned to the manufacturer, (ii) device design changes, 
(iii) device software upgrade, (iv) labelling changes, (v) changes in instructions 
for use or directions for use or technical manual, (vi) device destruction and  
(vii) device exchange. For more information, see [13].
3.4 Legal obligation
The submitted MDAE report does not have any legal implication concerning the 
reporters. The patients’ identity will be held under strict confidence and protected 
to its full extent. As the reporting programme is voluntary in nature, healthcare 
providers are encouraged to report adverse events for a better understanding of the 
risk associated with the use of medical devices, and to safeguard the health of the 
Indian population [14].
3.5 Essential data for effective reporting
This section includes the following information: date of event, reporter 
contact information, device name, manufacturer/importer/distributor details, 
catalogue number., lot/batch number., serial number., model number., date of 
implantation/explantation (if applicable), seriousness of the event, event descrip-
tion, patient history, patient outcome, healthcare facility information, root cause 
and corrective/preventive action [13].
3.6 Factors contributing to a serious adverse event
The improper functioning of the medical devices, manufacturing defects, 
design and labelling issues, user and procedural errors are some examples of the 
major contributing factors that can lead to the occurrence of a serious adverse event 
if underestimated [15].
4. Helpline facility for reporting adverse events
The IPC has already launched a toll-free helpline facility, helpline Number- 1800 
180 3024 (Monday to Friday- 9:00 am to 5:30 pm), for the reporting of adverse drug 
reactions by healthcare professionals and others [16]. Currently, this facility is also 
being extended to the report of any adverse event associated with the use of medical 
devices. Both the data management and the procedure adopted to receive the infor-
mation from the healthcare professionals, patients and others are given in Figure 3.
5. Enrolment process as MDMC under MvPI
Healthcare facilities including district/government/private hospitals, and autono-
mous bodies are recognized as MDMCs and AMCs respectively by the NCC-MvPI, 
IPC and NCC-PvPI, IPC. The function of MDMC is to raise awareness about the pro-
gramme and reporting of MDAEs. A ‘Letter of Intent’ is required to be submitted by 
the head of the Institution/hospital for participating in this nationwide programme to 
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monitor MDAEs [17]. After the suitability examination by the competent authority, 
the proposed centre may be recognized as an MDMC under MvPI. These centres are 
expected to collate data on adverse events associated with medical devices and IVDs 
under the MvPI and report them to the NCC-MvPI, IPC. For the proper functioning 
of MvPI activities in their respective centres, a research associate will be appointed by 
the NCC-MvPI, IPC [18]. The research associate will be responsible for the collec-
tion of reports and conduction of training programs on materiovigilance, aiming to 
sensitize the healthcare professionals and the general public. The technical team at 
the MDMC performs the validation of the report by carrying out the causality assess-
ment to identify any causal/temporal relationship between the event and the medical 
device. The workflow for determining the report responsible for the identification of 
adverse events significantly related to medical devices is shown at Figure 4.
Figure 3. 
Flow diagram representing the report of adverse events related to medical devices through helpline.
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6. Report Handling and Management
Initially, the reports are collected and analysed at the NCC-MvPI, IPC, by apply-
ing the globally recognized scientific standards/parameters to ensure the quality of 
the reports. In the second level, these analysed cases are forwarded to the subject 
expert group panel for review, and technical interpretation is drawn considering 
Figure 4. 
Medical device-related adverse events identification flowchart used at medical device adverse event monitoring 
centres (MDMC).
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both the clinical, as well as technical aspects. In the third level, these reports are 
placed before the core technical committee for the conclusions and recommenda-
tions, and are further forwarded to the national regulatory authority for implemen-
tation of the necessary actions (Figure 4) [19].
7. Data Generated
The NCC has collected the reported adverse events and provided a compari-
son of the serious adverse events reported in the index period from January to 
December during the years of 2018, 2019 and 2020. In total, NCC has received 3187 
adverse events, consisting of 1986 serious and 1201 non-serious events. Out of the 
serious adverse events reported, 23% were reported in 2018, 37% in 2019 and 40% 
in 2020. When comparing the reported data, an increase of 75% in serious adverse 
event reporting could be observed. Out of the adverse events reported, 73% of the 
reports were received from MAHs, 23% from MDMCs and 4% from AMCs [19]. 
This confirms and highlights the importance of the modalities developed, as they 
have significantly helped to improve the reporting of adverse events related to 
medical devices.
8. Conclusion
The tools developed for reporting may stimulate the communication between 
medical device users and the regulatory authorities to closely monitor medical 
device safety. In order to generate proper regulatory decisions and to ensure the 
quality and efficacy of the medical devices that are being sold and distributed in 
the Indian market, MvPI has shown to provide a robust and sustainable system for 
collecting and reporting adverse events associated with medical devices. This will 
highly encourage all the healthcare professionals, MAH and the public to efficiently 
report adverse events associated with medical devices.
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